• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification of novel therapeutic target for type 2 diabetes through genome-based drug discovery

Research Project

Project/Area Number 17K09886
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Endocrinology
Research InstitutionUniversity of the Ryukyus

Principal Investigator

Imamura Minako  琉球大学, 医学(系)研究科(研究院), 准教授 (00596124)

Co-Investigator(Kenkyū-buntansha) 前田 士郎  琉球大学, 医学(系)研究科(研究院), 教授 (50314159)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords2型糖尿病 / ゲノム創薬
Outline of Final Research Achievements

Genome-wide association studies (GWAS) have identified more than 200 genetic loci associated with susceptibility for type 2 diabetes (T2D). We have previously proposed several new potential pharmacological targets for T2D treatments using systematic bioinformatics approach integrating the findings of GWAS for T2D, and biological or pharmacological information from various databases. KIF11 is one of the potential therapeutic targets identified by the in silico pipeline. We have demonstrated that administration of KIF11 inhibitor ameliorated impaired glucose tolerance on db/db mice through increasing the insulin sensitivity and suppressing hepatic glucose production. The results suggest that our GWAS-based drug discovery platform is useful to identify novel drug targets for the treatment of common diseases, such as T2D.

Academic Significance and Societal Importance of the Research Achievements

近年のゲノム解析技術の進歩により、これまでに多くの2型糖尿病をはじめとする生活習慣病の疾患感受性遺伝子領域が同定されてきた。しかしながら、これらの成果の臨床への還元は十分に達成されておらず、ヒトゲノム研究成果の効率的な臨床応用手法の開発が現在の課題のひとつとなっている。本研究では新しいゲノム創薬手法により同定された新規候補治療薬の効果を in vivo 実験系で検証し得たことから、この創薬手法が有用であり、ゲノム研究成果の効率的な臨床応用に貢献しうることを示した。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (5 results)

All 2020 2019 2018 2017

All Presentation (5 results) (of which Int'l Joint Research: 2 results)

  • [Presentation] Genetics of type 2 diabetes and its implication for drug discovery2020

    • Author(s)
      Minako Imamura
    • Organizer
      The 1st International Symposium on Human InformtiX, Kyoto
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] In vivo evaluation of a novel therapeutic target for type 2 diabetes identified through genome wide association study-based drug discovery2019

    • Author(s)
      Minako Imamura, Masatoshi Matsunami, Shiro Maeda
    • Organizer
      EASD2019 (European Association for the Study of Diabetes),Barcelona, Spain
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] In vivo evaluation of a novel therapeutic target for type 2 diabetes identified through genome wide association study-based drug discovery2019

    • Author(s)
      Minako Imamura, Masatoshi Matsunami, Shiro Maeda
    • Organizer
      UNIV RYUKYUS & OIST JOINT SYMPOSIUM 2019, Okinawa
    • Related Report
      2019 Annual Research Report
  • [Presentation] 2型糖尿病ゲノム研究の現状~疾患感受性遺伝子Update 2018~2018

    • Author(s)
      今村 美菜子
    • Organizer
      第52回糖尿病学の進歩 (福岡) 平成30年3月2-3日
    • Related Report
      2017 Research-status Report
  • [Presentation] 2型糖尿病ゲノム研究の現状とその臨床応用~新しいゲノム創薬の可能性~2017

    • Author(s)
      今村 美菜子
    • Organizer
      第55回日本糖尿病学会九州地方会 (宮崎) 平成29年10月13日―14日
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi